Why the Immutep (ASX:IMM) share price is up 6% today

The Immutep Ltd (ASX: IMM) share price is soaring in early-afternoon trade following a collaboration agreement. Here's the latest.

The Immutep Ltd (ASX: IMM) share price is soaring in early-afternoon trade. This comes after the company announced a second clinical trial collaboration with subsidiaries of Merck & Co. (MSD). At the time of writing, the biotechnology company's shares are up 5.97% to 36 cents.

Five stacked building blocks with green arrows, indicating rising inflation or share prices

Image source: Getty Images

New Phase 2b trial

The Immutep share price is on the move as investors have been rallying up on the positive news.

According to its release, Immutep advised that it has entered a second clinical trial collaboration and supply agreement with MSD. This will see Immutep commence a new Phase 2b trial, named TACTI-003 using first-line head and neck squamous cell carcinoma (HNSCC) patients.

HNSCC is an aggressive life-threatening cancer that affects either the mouth, sinuses, nose or throat. The disease has a high mortality rate. Because of this, it is considered one of the most common cancers in the world. Global cancer statistics revealed 890,000 cases were diagnosed with 450,000 deaths reported in 2018 alone.

The trial will be a 1:1 randomised and controlled study involving around 160 first-line HNSCC patients. Furthermore, Immutep will seek to assess the safety and efficacy of its lead product candidate, eftilagimod alpha with MSD's KEYTRUDA (pembrolizumab). This will be compared against administering pembrolizumab alone to treat the HNSCC disease.

Immutep's TACTI-003 trial will take place over multiple locations across the United States, Australia, and Europe. Moreover, the first patient is expected to be enrolled in the study during the middle of this year.

It's worth noting that the company is also evaluating eftilagimod alpha and KEYTRUDA in its Phase 2 TACTI-002 trial. The encouraging results received led Immutep to conduct an additional TACTI-003 study.

Words from the CEO

Furthermore, Immutep CEO Marc Voigt touched on the company's developments, saying:

We are excited to be deepening our collaboration with MSD through this second agreement and the TACTI-003 clinical trial. Advancing to this later stage Phase IIb trial will allow us to explore the combination therapy in the commercially relevant 1st line therapy setting which has a high unmet medical need.

About the Immutep share price

The Immutep share price has gained close to 30% over the past 12 months. However, the company is down 13% year-to-date.

Based on the current valuations, Immutep has a market capitalisation of about $233.5 million. Additionally, Immutep has 648 million shares on issue.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ASX Share Market News

A little girl wearing wonky glasses checks out what's happening in the world on a mobile phone.
Broker Notes

Buy, hold, sell: Paladin Energy, Accent, Sigma Healthcare shares

Experts reveal the reasons behind their new ratings.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Opinions

3 reasons why I think this leading ASX 200 share is a buy

This underrated business could be a top buy today…

Read more »

Man in shirt and tie falls face first down stairs.
Record Lows

I think this ASX 200 stock looks like a bargain after hitting an all-time low: Here's why

The ASX shares fell another 8% on Tuesday.

Read more »

A woman looks excited as she fans out a wad of Aussie $100 notes.
Broker Notes

Macquarie predicts 90% upside and an 8% dividend yield for this ASX share

If the broker is right, this share will pay off nicely.

Read more »

Man working on a laptop from home.
ASX Share Market News

5 things to watch on the ASX 200 on Wednesday

It could be another tough session for Aussie investors on hump day.

Read more »

A woman sprints with a trail of fire blazing from her body.
Opinions

I hunted the ASX for shares with the potential to double. This one stood out

Do you have this ASX share in your investment portfolio?

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

A fit woman in workout gear flexes her muscles with two bigger people flexing behind her, indicating growth.
Opinions

I wanted growth, not hype. Only 3 ASX shares passed my checks

One of these ASX shares is tipped to climb up to 38%.

Read more »